Balanced news tone
News Sentiment
1652 sentiment intelligence
Fusen Pharmaceutical Company Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
71/100 classification confidence.
directly relevant articles
high-authority source matches
+1.0% over one week, -1.9% over four weeks, trend inactive, and near fair-value range.
Fusen Pharmaceutical Wins China Approval for New Doxazosin Extended-Release Tablets
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Fusen Pharmaceutical Wins China Approval for New Doxazosin Extended-Release Tablets
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 10 Jul 2026 12:41
- Source
- TipRanks
Fusen Pharmaceutical Shareholders Approve RMB300 Million Capital Injection into Henan Subsidiary
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 09:25
- Source
- TipRanks
Price to sales forward of Fusen Pharmaceutical Co., Ltd. – HKEX:1652
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 16:45
- Source
- TradingView
Exchange’s Disciplinary Action against Fusen Pharmaceutical Company Limited (Stock Code: 1652) and Five Current Directors
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jan 2023 08:00
- Source
- hkex.com.hk